Winther J, Overgaard J
Department of Ophthalmology, University Hospital of Aarhus, Denmark.
Acta Ophthalmol Suppl (1985). 1987;182:140-3. doi: 10.1111/j.1755-3768.1987.tb02614.x.
Combination therapy with a purified hematoporphyrin derivative, Photofrin II, and red light (photodynamic therapy) was investigated in a retinoblastoma-like tumour growing in the eyes of rats in vivo and in cell cultures. There was a marked dose-response relationship between Photofrin II and the light energy both in vitro and in vivo. Up to 33% of the tumours could be controlled in vivo. In vivo/in vitro assays indicated Photofrin II uptake in the tumour cells in vivo in relation to the administered doses. Studies of cell death kinetics suggested that the mechanisms of photodynamic therapy were both a primary cell kill effect and a secondary tissue destruction, probably as a consequence of vascular damage.
在体内大鼠眼部生长的视网膜母细胞瘤样肿瘤以及细胞培养中,研究了纯化的血卟啉衍生物(光敏素II)与红光联合治疗(光动力疗法)。在体外和体内,光敏素II与光能之间均存在明显的剂量反应关系。在体内,高达33%的肿瘤可得到控制。体内/体外试验表明,体内肿瘤细胞对光敏素II的摄取与给药剂量有关。细胞死亡动力学研究表明,光动力疗法的机制既有原发性细胞杀伤作用,也有继发性组织破坏,这可能是血管损伤的结果。